The impact of pricing strategy on the costs of oral anti‐cancer drugs

Abstract

Background The soaring costs of anti‐cancer drugs pose a threat to the sustainability of cancer care. The pricing strategy chosen by manufacturers can impact the costs of oral anti‐cancer drugs during dose modifications, but this issue remains under‐recognized in the literature. In general, with the flat pricing strategy, there is a single fixed price for each tablet regardless of dosage strength, whereas with linear pricing, the price of each tablet increases with its dose. We hypothesize that flat pricing will have increased drug costs compared to linear pricing during dose reductions since the cost remains fixed despite decreased dose requirements. This practice may have significant financial implications considering the high costs, extensive utilization, and frequent occurence of dose reductions with anti‐cancer drugs. Methods Oral anti‐cancer drugs reviewed by the pan‐Canadian Oncology Drug Review program between 2011 and 2018 were identified. The cost per mg and cost per 28‐day cycle were calculated for dose levels −2 to +2. The percent change in cost per mg and cost per cycle during dose modifications from the standard dose were calculated. We conducted Mann‐Whitney U and Fisher‐exact tests to compare the association between drug costs during dose reductions and pricing strategy. Results In this study, 30 oral anti‐cancer drugs for use in 41 indications were analyzed; 44% of drugs used linear pricing and 56% used flat pricing. Dose reductions increased the mean cost per mg for drugs with linear pricing by 14.7% (range: 0%‐50%) at dose level −1 and 17.2% (range: 0%‐50%) at dose level −2 and flat pricing by 60.8% (range: 19%‐100%) at dose level −1 and 99.1% (range: 0%‐300%) at dose level −2. The cost per mg was significantly increased in drugs using flat pricing compared to linear pricing when dose reduction to either level ‐1 ( P = 0.010) or level ‐2 ( P = 0.006) occurred. The mean cost per cycle was decreased for drugs using linear pricing by 20.9% (range: −40% to 0%) at dose level −1 and 48.7% (range: −60% to −25%) at dose level −2 and flat pricing by 0.8% (range −6% to 0%) at dose level −1 and 11.0% (range: −50% to 100%) at dose level −2. The cost per cycle was significantly decreased in drugs with linear pricing compared to flat pricing when the standard dose is reduced to either dose level ‐1 ( P = 0.005) or dose level ‐2 ( P = 0.026). Conclusions Overall, flat pricing had significantly greater costs compared to linear pricing during dose reductions of anti‐cancer drugs. While there is a general expectation that the cost of drugs should decrease with dose reduction, drugs with flat pricing were generally found to have increased cost per mg and no change in the cost per cycle. The resultant increased spending on drug acquisition (despite purchasing...

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

“…The pricing models for oral treprostinil and selexipag are not directly comparable, as oral treprostinil is based on a price-per-dose model, with increased pricing for higher-dosage tablets, whereas selexipag is based on a fixed price that does not vary by dose. While fixed pricing, regardless of dosage, is often perceived as less costly and predictable [29], dose-based pricing can result in lower costs with dose reductions [30]. This study showed that, for oral prostacyclin drugs used in patients with PAH, treprostinil dose-based pricing led to lower pharmacy costs than the fixed pricing associated with selexipag.…”

Untitled

“…O atual modelo de definição de preços brasileiro é focado na proporcionalidade de concentração de princípio ativo, enquanto alguns modelos internacionais são focados no tratamento e, por isso, podem ter preço flat (mesmo preço para apresentações com concentrações diferentes) (Brasil, 2004;Clarivate Analytics, 2020aTruong et al, 2019).…”

Strategies of drugs cost containment in hospital: A systematic literature review

“…• Intervention of drug cost management will be effective. others were conducted on the pricing of prescription drugs to reduce costs, [13][14][15][16] and some of them have examined the cost of drugs in the ICU and emergency department. [17][18][19] Reducing the costs of the health system, especially hospitals, has always been a concern for policy makers and managers.…”

“…Accordingly, many studies have been conducted on reducing drug costs. A number of these studies have analysed the cost of antibiotics, 8–12 some others were conducted on the pricing of prescription drugs to reduce costs, 13–16 and some of them have examined the cost of drugs in the ICU and emergency department 17–19 …”